Autres langues Simcere Pharmaceutical Group Limited

Actions

2096

HK0000658531

Produits pharmaceutiques

Marché Fermé - Hong Kong S.E. 10:08:16 07/09/2026			Varia. 5j.	Varia. 1 janv.
11,58 ^HKD	-0,43%		+4,32%	-3,26%

04/09	Le Yingmule de Simcere Pharma reçoit l'autorisation de mise sur le marché en Chine pour la prévention du VRS	MT
01/09	Roche signe un accord de licence mondial pour un traitement expérimental de Simcere contre le cancer du sang	RE

Autres langues

04/09	Simcere Pharma's Yingmule Gets China Marketing Approval for RSV Prevention
03/09	Aktien Schweiz: SMI muss überraschend hohe Inflation verdauen
03/09	Aktien Schweiz Vorbörse: Leicht freundlich - Inflation und BIP im Blick
03/09	Hutchmed Enters Licensing Agreement With GSK for Cancer Drug
02/09	Aktien Schweiz gut behauptet - SMI von defensiver Ausrichtung gestützt
02/09	MORNING BRIEFING - Deutschland/Europa -2-
02/09	Roche lizenziert Rechte an Antikörper von chinesischer Simcere Pharma ein
02/09	Roche, Simcere Pharma Strike Drug Licensing Deal
01/09	Roche signs global licensing pact for Simcere's experimental blood cancer drug
01/09	Simcere Pharma Licenses Cancer Drug to Roche
01/09	Roche signs global licensing pact for Simcere's B-cell cancer drug candidate
01/09	Simcere Pharmaceutical Group Limited And F. Hoffmann-La Roche Ltd Enter Into Exclusive Licensing Agreement For SIM0660
21/08	Simcere Pharmaceutical Group's H1 Attributable Profit Rises 38%
20/08	Simcere Pharmaceutical Group Limited Reports Earnings Results for the Half Year Ended June 30, 2026
20/08	Simcere Pharmaceutical Group Limited Announces Management Changes, Effective August 20, 2026
30/07	Simcere Pharmaceutical Group Limited Provides Consolidated Earnings Guidance for the Six Months Ended June 30, 2026
09/07	Simcere Pharma's Acute Ischemic Stroke Included in National Essential Medicines List
15/06	Simcere Pharma Gets China Nod for Tumor Drug Trial
12/06	Simcere Pharmaceutical Group Limited Receives Clinical Trial Approval for Sim0689 Pd-1/Vegf Bispecific Antibody
12/06	Simcere Pharmaceutical Group Limited Approves Final Dividend for the Year Ended December 31, 2025, Payable on or Before July 13, 2026
12/06	Simcere Pharmaceutical Group Limited Enters into A Research Collaboration Agreement with Stanford Medicine to Develop Innovative Therapies for Patients with Idiopathic Pulmonary Fibrosis
12/06	Simcere Pharmaceutical Enters into a Research Collaboration Agreement with Stanford Medicine to Develop Innovative Therapies for Patients with Idiopathic Pulmonary Fibrosis
02/06	Simcere Pharma Wins Promotion Rights for PrimeGenX's Atopic Dermatitis Drug
01/06	Simcere Pharmaceutical Group Limited Enters into Exclusive Promotion Service Agreement with PrimeGenX Therapeutics Co., Ltd
21/05	Simcere Pharmaceutical Group Limited Proposes to Declare A Final Dividend for the Year Ended December 31, 2025